Ondine receives CE Mark approval for Periowave for gum disease

By Lisa Kerner

Erie, Pa., March 30 - Ondine Biopharma Corp. received CE Mark approval for its proprietary Periowave Photodynamic Disinfection System for the treatment of periodontal (gum) disease, which affects one-third of all adults and over half of the population over the age of 50.

"CE Mark approval permits us to expand our market reach beyond Canada, where Periowave is currently being sold," president and chief executive officer Carolyn Cross said in a company news release.

"The CE Mark also indicates that we have met the essential health, safety and environmental protection requirements detailed in the European Directives covering medical devices."

Periowave uses low-intensity lasers and wavelength-specific, light-activated compounds to target and destroy microbial pathogens and reduce the symptoms of periodontal disease.

Ondine develops non-antibiotic therapies for the treatment of bacterial, fungal and viral infections. The company is based in Vancouver, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.